Clinical trial
A Phase II Open-label Study of Duloxetine to Reduce Inflammatory Bowel Disease-Related Disability and Psychological Distress
NCT07431606 is registered in ClinicalTrials.gov with University of Pennsylvania as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Open-label Study of Duloxetine to Reduce Inflammatory Bowel Disease-Related Disability and Psychological Distress
- Lead sponsor
- University of Pennsylvania
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- May 1, 2026
- Completion date
- October 31, 2027
- Enrollment
- 32 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.